Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: A single center experience with 14 patients

World Journal of Urology

Volumn 29, Issue 3, 2011, Pages 355-360

  Seidel, C ^a   Fenner, M ^a   Merseburger, A S ^a   Reuter, C ^a   Ivanyi, P ^a   Langer F ^a   Ganser, A ^a   Grunwald V ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Primary; RECIST; Renal cell carcinoma; Renal lesions; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; SUNITINIB;

ADULT; AGED; ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; HUMAN; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; NEPHRECTOMY; PALLIATIVE THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PALLIATIVE CARE; PROTEIN-TYROSINE KINASES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79957477589     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0642-3     Document Type: Article

References (21)

1. Novick AC, Campbell SC (2002) Renal tumours. In: Walsh PC, Retik AB, Vaughan EDJ, Wein AJ (eds) Campbell's urology. WB Saunders, Philadelphia, pp 2672-2772.
2. Umed T, Niijima T (1986) Phase II study alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 58(6): 1231.
3. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659.
4. Mickisch GH, Garin A, van Poppel H, De Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970.
5. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335: 865-875.
6. Fishman M, Seigne J (2002) Immunotherapy of metastatic renal cell cancer. Cancer Control 9: 293-304.
7. Pezaro C, Davis ID (2008) Targeted therapies in the treatment of renal cell carcinoma. Curr Med Chem 15(12): 1166-1174.
8. Saylor PJ, Michaelson MD (2009) New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 7(6): 645-656.
9. Motzer RJHT, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(352): 115-324.
10. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14(8): 2431-2436.
11. Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2): 518-523.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45(2): 228-247.
13. Szczylik C, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee S, Carteni G, Hariharan S, Gore ME (2008) Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 (May 20 suppl): p abstr 5124.
14. Wood L, Garcia JA, Elson P, Salas RN, Lane BR, Klein E, Stephenson A, Dreicer R, Campbell SC, Rini BI (2009) Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). J Clin Oncol 27: 15 s, (suppl; abstr 5096).
15. Wood CG, Margulis V (2009) Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115(10 Suppl): 2355-2360.
16. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25): 4076-4081.
17. Biswas S, Kelly J, Eisen T (2009) Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14(1): 52-59.
18. Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. Mar 23. [Epub ahead of print].
19. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068 Epub Jan 25 2010.
20. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111.
21. Heng DY, Park T, Bjarnason GA, Vaishampayan UN, Tan M, Knox JJ, North SA, Kollmannsberger CK, Rini BI, Choueiri TK (2010) Progression-free survival (PFS) as a predictor of overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. ASCO Genitoruniary Cancers Symposium Abstract No. 329.